Hepatocellular carcinoma (HCC) is a leading cause of cancer in West Africa where HBV infection is endemic. However, limited information is available on other risk factors such as alcohol use, HCV and HIV infection. A case-control study was conducted in referral hospitals of Abidjan (Cote d'Ivoire), Bamako (Mali) and Lome (Togo). Cases were matched with controls on age, gender and participating site. The diagnosis of HCC relied on the combination of one or more space-occupying lesions suggestive of an HCC on a standardized abdominal ultrasound and an a-fetoprotein level 400 ng/ml. HIV, HBV and HCV serology were performed. Hazardous alcohol use was assessed using the AUDIT questionnaire. A conditional logistic regression model was used to measure odds ratio (OR) with their 95% confidence intervals (CI). A total of 160 cases and 320 controls were included. Cases were predominantly men (80.0%) with a median age of 47 years Hepatocellular carcinoma (HCC) is the second most common cause of death from cancer worldwide and a leading cause of cancer in most West African countries (second in men and third in women) with over 20,000 incident cases and 20,000 deaths each year.
Hepatocellular carcinoma (HCC) is a leading cause of cancer in West Africa where HBV infection is endemic. However, limited information is available on other risk factors such as alcohol use, HCV and HIV infection. A case-control study was conducted in referral hospitals of Abidjan (Cote d'Ivoire), Bamako (Mali) and Lome (Togo). Cases were matched with controls on age, gender and participating site. The diagnosis of HCC relied on the combination of one or more space-occupying lesions suggestive of an HCC on a standardized abdominal ultrasound and an a-fetoprotein level 400 ng/ml. HIV, HBV and HCV serology were performed. Hazardous alcohol use was assessed using the AUDIT questionnaire. A conditional logistic regression model was used to measure odds ratio (OR) with their 95% confidence intervals (CI). A total of 160 cases and 320 controls were included. Cases were predominantly men (80.0%) with a median age of 47 years Hepatocellular carcinoma (HCC) is the second most common cause of death from cancer worldwide and a leading cause of cancer in most West African countries (second in men and third in women) with over 20,000 incident cases and 20,000 deaths each year. 1 Hepatitis B and C viruses (HBV, HCV) are the two main causes of HCC worldwide, HBV being highly prevalent in West African countries. 2, 3 Although the association between chronic hepatitis viruses and HCC was reported form the Gambia, limited information is available from other parts of West Africa. 4 Aside chronic viral hepatitis, limited information is currently available on other risk factors that might contribute to the occurrence of HCC in Africa. Alcohol use, a well-known risk factor of HCC, is characterized by the diversity of drinking patterns across sub-Saharan Africa while being a significant contributor in terms of deaths. 5, 6 However, no information is available on the specific role of alcohol use on the occurrence of HCC in Africa. In high-income countries, the incidence of HCC was reported to be significantly higher in HIV-infected people with AIDS compared to the general population with a reported standardized incidence ratio of 5.6 [95% CI 4.0-7.7] for HCC. 7 In sub-Saharan Africa, reports on the epidemiological association between HCC and HIV infection are limited and conflicting. While early reports failed to find any association between HIV and HCC, recent case-referent studies conducted in West Africa identified a significant association, but the limited number of patients included and the absence of any adjustments on essential confounding factors such as viral hepatitis warrants further investigations. [8] [9] [10] There is currently no or limited curative treatment for HCC available in sub-Saharan Africa resulting in a particular dramatic prognosis of this cancer with an estimated median survival after diagnosis below three months. 11 It is therefore crucial to accurately document the respective role of etiological factors leading to HCC as prevention and early diagnosis are key components in the fight against this malignant condition.
Methods
A case-control study was conducted in referral hospitals managing HCC in Abidjan (Cote d'Ivoire), Lome (Togo) and Bamako (Mali). In the participating hospitals, clinical wards following adult patients seeking for care with a diagnosis of primary liver cancer were solicited to participate. In each wards, a dedicated medical referent was in charge to prospectively include every patient with a suspected diagnosis of HCC.
In high-income countries, the diagnosis of HCC usually relies on cytology and/or histology combined with computed tomography (CT) or magnetic resonance imaging. 12, 13 In sub-Saharan Africa, these imaging resources are not widely available and liver biopsy is rarely performed in suspected cases of HCC facing the lack of curative treatment to be proposed and the morbidity associated to this invasive technique (bleeding or needle-track seeding). 14 Suspected cases of HCC underwent a systematic standardized abdominal ultrasounds examination combined with a plasmatic a-fetoprotein (AFP) measurement for diagnostic confirmation. The diagnosis of HCC was defined as the combination of one or more spaceoccupying well-characterized tumors 2 cm, suggestive of an HCC and a plasmatic AFP 400 ng/ml. In a few cases of abdominal ultrasound highly suggestive of HCC with a serum AFP <400 ng/ml, an abdominal CT scan was requested for diagnostic confirmation. All cases of HCC were systematically reviewed and confirmed by a panel local gastroenterologists and cancer specialists. A control group (two controls for one case of HCC) of hospitalized patients seeking care in the same teaching hospitals were recruited in wards not related to cancer or diseases reported in the literature as associated with infectious diseases including orthopedic surgery, cardiovascular disease and endocrinology wards. All included controls needed to have a clear primary diagnosis that motivated their access to care. Controls were matched with cases on age (62 years), gender and participating referral hospital. Facing the high prevalence of HBV in West Africa, all control participants underwent a systematic standardized abdominal ultrasounds examination combined with a plasmatic AFP measurement to discard any subclinical HCC.
Clinical monitors were in charge to collect the patient's informed consent and administered a dedicated questionnaire during face-to-face interviews. Sociodemographic characteristics were recorded including age, gender, place of living, formal education and income. The alcohol use disorder identification test (AUDIT) was administered during the interview to assess alcohol consumption within the past year. It is a 10-item questionnaire, each item scored from 0 to 4 points, giving a maximum total score of 40 points. 15 A criterion score 8 on the AUDIT characterized hazardous drinking. Clinical monitors were previously trained to the identification of a standard alcohol drink (approximately 10-14 g of pure alcohol). They were asked to adjust the number of drinks in the response categories according to drink sizes and alcohol type stated by patients.
Laboratory measurements
Cases and controls included in this study underwent a systematic HIV1/2 serology using the Determine TM HIV1/2 For the quantitative determination of plasmatic AFP, a chemiluminescent microparticle immunoassay was used in Bamako; (Architect TM AFP assay, Abott Diagnostics). In Lome and Abidjan, AFP was measured using an automated quantitative enzyme linked fluorescent assay (mini-VIDAS TM AFP, Biomerieux, Marcy-L'Etoile, France). Results were reported in nanogram per milliliter.
The quantification of HBV viral load (VL) was performed using the COBAS(R) AmpliPrep/COBAS(R) TaqMan(R) v2.0 (Roche V R ) kit. A threshold >20 IU/ml was considered to define HBV VL detectability. HBV genotype was determined using an in-house assay. Extracted DNA was used in nested-PCR amplification of pol gene using two sets of primers in a GeneAmp PCR System 9700 (Applied Biosystems, Courtaboeuf, France) thermal cycler. Nucleotide sequences of the 808 pb fragments were obtained by direct sequencing of the amplified DNA, using the inner primers of each PCR using a 3.1 Bid dye terminator kit on an automated 3130 DNA analysis system (Applied Biosystems, Courtaboeuf, France). To identify the subtypes, the derived nucleotide sequences of pol regions were aligned by the Clustal W multiple sequence alignment program with known reference strains. Antihepatitis delta virus (HDV) antibodies were measured with the ETI-AB-DELTA-2 Kit (DiaSorin S.A., Antony, France). The quantification of HBV viral load and the identification of both HBV genotype and HDV antibodies were performed at the virology unit in Abidjan for all samples. The presence of a detectable HBV viral load was tested in all participants with a positive HBs Ag if sufficient remaining plasma samples were available. To document occult HBV infection, HBV viral load was also tested in all HBs Ag-negative/anti-HBc Ab-positive HCC and a randomly selected sample of HBs Ag-negative/anti-HBc Ab-positive participants in the control group. All commercial laboratory tests were performed according to the manufacturer's specifications.
Statistical analysis
A conditional logistic regression model was used to measure the association between HCC and available factors of interest. Analyses were computed with the PHREG procedure by using the discrete logistic model and forming a stratum for each matched set of one cases and two controls in the SAS 9.3 software (SAS Institute Inc., NC, USA). Explored etiologic factors including hazardous drinking, HBV, HCV and HIV infection were included in the multivariate model regardless of their statistical association with HCC. Other relevant potential confounders were tested and included in the final model using a stepwise descending procedure. A p value of <0.05 was considered for statistical significance. Odds ratio (OR) estimates were reported with their 95% confidence interval (CI).
The population attributable risk (PAR) for the development of HCC was estimated for the main known etiological factors measured including HBV, HCV infection and hazardous alcohol consumption using the following formula: PAR5 p 3 (OR 2 1)/(p 3 OR) 1 (1 2 p). The "p" reefers to the prevalence of the etiological factor in the control population taken as a proxy for the prevalence of the etiological factor in the general population. The OR was taken as a proxy for the relative risk associated with exposure to the etiological factor.
Results

General characteristics
Of the 179 suspected cases of primary liver cancer initially recruited, 19 were subsequently excluded for not meeting criteria of HCC diagnosis. A total of 160 cases of HCC and their 320 matched patients were finally included in three participating countries: 44 cases (88 controls) in Cote d'Ivoire, 40 cases (80 controls) in Togo and 76 cases (152 controls) in Mali.
The median age of the 160 patients with HCC was 47 years [Interquartile range (IQR) 38-57] and 128 (80.0%) were men (Table 1) . A higher proportion of men was observed throughout the different age classes but was less pronounced in the 65-year age class compared to younger patients ( Figure 1 ). The overall prevalence of hazardous alcohol use, Ag HBs, anti-HCV Ab and anti-HIV Ab in cases of HCC was 16.2%, 70.0%, 27.5% and 4.4%, respectively. A high prevalence of positive HBs Ag (>60.0%) was observed throughout the age classes except for patients 65 years (12.5%) (Figure 2 ). Contrastingly, a steep increase of anti-HCV antibody positivity was observed with age, from 10.3% in HCC cases <35 years to 66.7% in patients 65 years (p trend < 10 
Characteristics of HBV-infected participants
A total of 143 HBV-infected participants were diagnosed based on a positive HBs Ag, including 112 cases of HCC and
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31 controls. In participants with a positive HBs Ag, 137 HBV viral load were tested (six missing values due to insufficient remaining plasma sample) and 130 presented with a detectable HBV viral load. In participants with a detectable HBV replication, the median HBV viral load was significantly higher in cases of HCC (5.8 log10 copies/ml [IQR 3.9-6.6]) compared to HBV-infected controls (2.5 log10 IU/ml [IQR 1.9-3.8]) (p < 10 24 ) ( Table 3 ). In HBs-positive participants, 132 were tested for anti-HDV antibody (11 missing values due to insufficient remaining plasma sample). The prevalence of positive anti-HDV antibody was 27.8% in Lome, 12.3% in Bamako and no case reported in Abidjan (p 5 0.002). No significant difference in the prevalence of anti-HDV antibody was reported between cases of HCC (14.6%) and controls (10.3%) (p 5 0.37).
The presence of an occult HBV infection was tested among 94 HBs Ag-negative/anti-HBc Ab-positive participants, including 41 cases of HCC and 53 participants from the control group. The overall prevalence of occult HBV infection in these participants was 9.6%; 14.6% in cases of HCC and 5.7% in the control group (p 5 0.17). Participants with an occult HBV infection were significantly older (56 
Factors associated with HCC and population attributable risk
In an adjusted logistic model, hazardous alcohol use (OR Table 4 ). The PAR of HBV infection, HCV infection and hazardous alcohol use was 85.6%, 62.1% and 14.9%, respectively. In a subanalysis combining the effect of HBV infection with hazardous alcohol use, HBV-infected patients with hazardous drinking had an OR of 149.8 (95% CI 13.5-1 667.0) and HBV-infected patients with no hazardous drinking an OR of 57.4 (CI 18.8-175.3) (reference group: HBV-negative patients with no hazardous drinking) (Supporting Information). Combining the effect of HBV infection with HCV infection, HBV/HCV co-infected patients had an OR of 99.0 (95% CI 8.0-1 229.6) and HBV-infected patients with no HCV infection an OR of 87.8 (CI 24.7-312.1) (reference group: HBV-/HVC-negative patients).
Discussion
Our study confirms that infection with chronic viral hepatitis B and C were identified as the major contributors to HCC in West Africa. 3, 4 The fraction of HCC potentially preventable by the elimination of HBV infection was particularly high and quite homogeneous across participating countries. In addition, hazardous alcohol use was identified as significantly associated HCC with major differences of alcohol exposure according to participating countries.
Demographic characteristics of HCC showed a high sex ratio, consistent with previous reports. 4, 16 Mechanisms leading to a higher proportion of men are not well understood but potentially the result of a higher proportion of chronic HBV infection reported in men compared to women. 17, 18 Biological mechanisms have also been suggested as HCC is suspected to be a type of hormone-responsive tumor, more susceptible to occur in men and postmenopausal women. 19 Indeed, the higher proportion of women with HCC reported in the >65 year age-class compared to younger age might support this last hypothesis. The seroprevalence of HBV across age classes showed a significant decrease in older patients with HCC (and in controls; data not shown) probably reflecting the loss of the HBs Ag over time. 4, 20, 21 The higher rate of occult * declared alcohol use during the past year assessed using the alcohol use disorder identification test; a score > 7 was used to define hazardous drinking. Abbreviations: HBs, hepatitis B surface; HBc, hepatitis B core; HCV, hepatitis C virus; HIV, human immunodeficiency virus.
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HBV reported in older participant raises questions on HBV screening and care of this particular population. Previous cohort studies from South East Asia and North America have identified that high serum HBV DNA level was a major risk predictor of hepatocellular carcinoma independent of other HBV biomarkers in HBV-infected persons. 22, 23 In our study, a three-log increase of HBV viral load was reported in HCC cases compared to control participants with a positive HBs Ag. As characteristics of HBV infection (i.e., modes of HBV transmission, HBV genotype. . .) differs in sub-Saharan Africa compared to other settings, well characterized cohort studies of HBV-infected patients are needed to document and validate predictors of HCC risk in African populations. Observational cohorts studies suggest a protective effect of antiviral treatment on the risk of incident HCC. [24] [25] [26] [27] It is therefore crucial to enable access to HBV viral load monitoring and antiviral treatment to HBVinfected patients as it might prevent a significant proportion of HCC, especially given the limited number of patients eligible to treatment. 17, 28 The prevalence of HDV reported in the present study is concordant with results from a recent systematic review where pooled HDV seroprevalence ranged from 7.3% (CI 3.5-12.2) in the general population to 9.6% (CI 2.3-20.4) in liver-disease population across West Africa. 29 Interestingly, marked differences in HDV prevalence were reported according to countries. This finding is consistent with previous reports where the prevalence of a positive HDV serology in blood donors ranged from <1% in the Gambia to 20% in Mauritania suggesting that HDV infection might not be equally distributed across west Africa but probably present in localized clusters. 17, 30 As HDV is associated with accelerated liver disease progression in HBV-infected persons and poorly accessible to efficient treatment, screening remains a priority. 31, 32 Larger and more representative epidemiologic studies are needed at each national level to better characterize the burden of HDV.
HCV infection was also identified as an important contributor to the burden of HCC in West Africa. Contrarily to HBV infection, the prevalence of HCV in participants with HCC was low in younger age class and represented the main HCC risk factor in patients >65 year old. The positive association between age and HCV infection might be the result of a cohort effect as previously reported in the Gambia. 4 Modes of transmission of HCV in Africa are incompletely documented but iatrogenic transmission probably played a significant role. 33, 34 Therefore, efforts to prevent unsafe injection might have resulted in lowering the overall prevalence of HCV infection in younger populations. In addition, transmission of HCV infection is likely to occur later in life compared to HBV infection, which is essentially transmitted from mother to child or in early childhood. 35 Combined with a median latency period between a primary HCV infection and the development of HCC of 30 years, these arguments could explain the predominance of HCV-related HCC in older participants. 36 While new potent direct-acting antiviral therapies to cure HCV infection become available, initiatives to make these drugs available in West Africa could potentially play an important role in the prevention of HCC. 37 Hazardous alcohol use was not uncommon but varied greatly according to participating sites. Patients from Mali, which is predominantly Muslim, harbored a low level of declared alcohol use compared to Cote d'Ivoire and Togo reflecting the various levels of alcohol use reported across subSaharan Africa. 5 Hazardous alcohol use was significantly associated with HCC in our analysis although not reaching the magnitude of association reported with chronic viral hepatitis. However, it is the first report to our knowledge that measured the direct impact of alcohol misuses on HCC in sub-Saharan Africa. While the synergic impact of alcohol use and HCV on HCC has been well studied, the interaction between alcohol use and HBV infection in the occurrence of HCC remains less reported. 38, 39 Between an additive and a multiplicative effect of hazardous drinking and HBV infection was reported towards HCC given the threefold increase OR associated with HBs Agpositive hazardous drinkers versus HBs Ag-positive participants declaring no/moderate drinking. This effect is consistent with the few studies reporting a higher risk of HCC in HBVinfected patients with a heavy alcohol consumption compared to moderate users/abstinent patients. [40] [41] [42] It is therefore essential that national programs integrate screening and prevention of alcohol misuses in the fight against HBV infection in subSaharan Africa.
In high-income countries, the incidence of HCC in HIV-positive patients is significantly higher compared the general population and increasing over time. 7 Reasons for this association have not yet been entirely elucidated but the high prevalence of HCV infection (and to a less extent HBV infection) in HIV-infected people probably plays a prominent role. Aside the higher burden of chronic viral hepatitis observed in HIV-infected patients, decreased immune function induced by HIV directly enhance hepatitis viral replication leading more rapidly to HCC as supported by the elevated rate of HCC among organ transplant recipients. 43 In our case-control study, HIV infection was not associated with HCC. Reasons for this absence of association can be multiple; contrarily to highincome settings, the prevalence of HBV infection has been reported as similar in HIV-infected persons compared to HIV-negative persons in sub-Saharan Africa. 44 Beyond these considerations, the cross-sectional design of the study combined with the limited sample size might have prevent any reported association given the lower than expected prevalence of HIV infection observed in the control group. Large prospective studies measuring the occurrence of HCC in HIV-infected cohorts need to be set up in subSaharan Africa. Facing the particularly high burden chronic viral hepatitis, HCC and HIV in sub-Saharan Africa and the relatively small amount of research dedicated to these associations, a greater understanding of HIV/HBV interactions in the occurrence of HCC should be considered as a high priority.
Limitations
The use of ultrasonography combined with the AFP serum biomarker is currently not considered as the international 
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reference to support the diagnosis of HCC. However, systematic liver biopsy was not achievable in this context. To enhance de reliability of our case definition, we choose to restrict our inclusions to well-characterized tumors 2 cm. This approach might have induced some over-representation of advanced HCC, disregarding early stage HCC < 2 cm. Nevertheless, most of the patients diagnosed with HCC in real-life conditions are detected upon clinical stage with an advanced disease. The level and duration of alcohol intake on the risk of HCC is still controversial. Therefore, the use of AUDIT score might not be optimal to define the risk of HCC. Nevertheless, this score provides useful approach to measure alcohol intake in a standardized way across various participating sites. The screening of chronic viral hepatitis and HIV infection relied on serological assays that differed according to participating countries. In addition, positive cases of anti-HCV Ab were not confirmed by PCR HCV RNA allowing for potential bias of measurement. However, the reported prevalence of HBV, HIV and HCV infections from the control group are quite concordant with prevalence estimates from the respective participating countries.
Conclusion
Aside the independent association of Alcohol use, HBV and HCV infection with HCC reported here, HBV and HCV infections were identified as the major contributors in terms of HCC attributable risk. Current efforts to expand birth HBV vaccination in West Africa will potentially have a major impact on HCC incidence in the future, if correctly implemented. However, a timely access to screening and treatment of HBV and HCV represent an emergency to prevent forthcoming HCC among older persons, highly exposed to HCV and who did not benefit from HBV vaccination programs. In HBV-infected patients, HBV viral load was identified as a key determinant associated with HCC, highlighting the crucial need to a large and affordable access to HBV viral load monitoring in patients screened with a positive HBs Ag to manage liver disease progression. A synergic effect between hazardous alcohol use and HBV infection on the risk of HCC was identified. Therefore, combining screening and care of HBV infection together with hazardous drinking should be promoted given the importance of hazardous alcohol use in some parts of West Africa.
Overall, these findings contribute to a better knowledge of determinants associated with HCC risk in West Africa, an essential step toward future HCC prevention strategies in this endemic setting.
